At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multi-site Study of Autologous Cord Blood Cells for Hypoxic (HIE)
In Brief
A Phase 2 clinical trial evaluating Infusion of autologous cord blood and Placebo for Moderate or Severe Hypoxic-ischemic Encephalopathy in Newborns. Completed, enrolled 35 participants across 1 site.
Detailed Summary
This study will test the safety and efficacy of an infusion of a baby's own (autologous) umbilical cord blood as compared with placebo in babies born with history and signs of hypoxic-ischemic brain injury.
Study Details
Timeline
Interventions
Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.